| | “The Trends Behind Successful Cancer Treatments” Powerful new cancer treatments such as CAR T-cell therapy, anti-cancer vaccines and immunotherapies are showing unprecedented response rates and bringing patients new hope. The uptick of successes are generating optimism among scientists and companies looking to get their drug to market. Is your approach setting you up for success? Unlock More Potential with TD2. |
Today's Rundown KRAS craze sees Merck put $2.5B biobucks down for Taiho, Astex licensing deal In a rush? A year after exiting stealth mode, Black Diamond guns for IPO BeiGene bags option on Leap cancer drug, requests PD-1 combination trial Novo Holdings tweaks fund to take antibiotics deeper into the clinic ATAI backs Neuronasal's through-the-nose concussion treatment The top 10 largest biopharma M&A deals in 2019 Featured Story | | | Monday, January 6, 2020 KRAS and its hope against cancer was one of the biggest talking points in 2019, and it seems this hype is not dying down in 2020. |
|
|---|
|
Top Stories Monday, January 6, 2020 Last year, we asked: Are too many early-stage biotechs going for IPOs, and when will the bubble burst? Monday, January 6, 2020 BeiGene has optioned the rights to Leap Therapeutics’ cancer drug DKN-01 in most of the Asia-Pacific region. The deal gives BeiGene the chance to combine Leap’s anti-DKK1 antibody with its recently approved anti-PD-1 checkpoint inhibitor. Monday, January 6, 2020 Novo Holdings has changed the scope of its REPAIR Impact Fund to enable it to bankroll antibiotics for longer. REPAIR began life focused on projects between lead optimization and phase 1, but, in light of the tough funding environment for anti-infectives, will now support programs into phase 2. Monday, January 6, 2020 There is no medicine for people who suffer concussions. Instead, they are told to avoid certain activities, so their brains can rest and recover. To change that, ATAI Life Sciences is backing Neuronasal's mission to develop a drug delivered via the nose that can stop the "biochemical cascade" behind short- and long-term concussion symptoms. Biopharma M&A got a big boost moneywise in 2019. The three largest delivered more than $150 billion, with Bristol-Myers Squibb's $74 billion takeover of Celgene setting a new record. Oncology was still a hot theme, stringing through a whole year of big dealmaking headlines, just as gene therapy gained popularity. | | Experts in our field; with 20+ years’ experience in Viral Vector & plasmid DNA (R&D, High Quality and GMP) manufacture for pre-clinical, clinical & commercial supply. Take a virtual tour of our facilities & find out more about our expansion project. |
Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|---|
|
Resources Sponsored by: ICON Clinical Research Ltd The beginning of this digital transformation is well underway and is likely to accelerate. Read our white paper, “Digital Disruption in Biopharma: How Digital Transformation can reverse declining ROI on R&D,” to learn more. Sponsored by: snapIoT, Inc. Download this white paper and read the expert feedback that snapIoT has gathered from industry thought leaders on the evolution, evaluation, and use of telemedicine solutions in clinical trials. Sponsored by: EVERSANA How are your launch strategies can convert “innovation” into value for patients? Sponsored by: Eli Lilly and Company in partnership with Xcenda Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system. Sponsored by: Amazon Web Services From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks Sponsored by: Outer Edge Technology, LLC Why companies leverage the expertize of industry focused cloud service providers to design and build quality systems and facilitate the FDA Validation of Mission Critical Apps in the Cloud. Sponsored by: Colorcon Learn more: Best practices for defending supply chain security and compliance by efficiently managing product authentication. Sponsored by: Metabolon Small or emerging pharmaceutical and biotech companies pursuing novel molecules and targets have two important goals: achieve clinical success and attract new rounds of funding. While there’s never a guarantee of either, certain actions can influence the outcome in your favor. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. Asia-Pacific Healthcare Compliance Certificate Program March 9-12, 2020 FierceBiotech Executive Breakfast at the J.P. Morgan Healthcare Conference 2020 January 14, 2020 | The Fairmont Hotel | San Francisco, CA 11th Annual SCOPE Summit: Summit for Clinical Ops Executives February 18-21, 2020 | Orlando, FL BIO International Convention June 8-11, 2020 | San Diego, CA Middle East Healthcare Compliance Certificate Program March 23-26, 2020 | 